Azithromycin Combination Therapy for Malaria

Status Completed

Clinical Trial Summary

The goal of this study is to develop a safe, well tolerated, and highly efficacious azithromycin combination treatment for uncomplicated falciparum malaria. Azithromycin is a drug that has shown potential for malaria treatment. It will be combined with other malaria drugs currently approved for treatment in Thailand. About 120 people, ages 20-65, will be enrolled in Thailand. Participants will have severe cases of malaria and they will be hospitalized 28 days for treatment.

Clinical Trial Description

The study is aimed at identifying a well tolerated, practical and highly efficacious treatment regimen of azithromycin in combination with artesunate or quinine for uncomplicated falciparum malaria for future studies, to monitor for the tolerability and safety of these combination regimens and to compare tolerability, safety and efficacy of azithromycin when given in combination with artesunate as compared to quinine. This study is also aimed at comparing tolerability, safety and efficacy of the combination of artesunate and azithromycin when given as a single daily dose (200mg As+1000mg Az) for 3 days as compared to 2 doses of 100mg As+750mg Az per day for 3 days and to compare the tolerability, safety and efficacy of the combination of quinine and azithromycin when given as 3 daily doses of quinine (10mg/kg) + Az 500mg vs. 2 daily doses of quinine (10mg/kg) + Az 750mg when given for 3 days. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00299208
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 2
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04577066` - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.	Phase 1/Phase 2
Completed	`NCT01883609` - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S	Phase 1/Phase 2
Completed	`NCT00593398` - Malarial Immunity in Pregnant Cameroonian Women
Completed	`NCT01659281` - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand	N/A
Completed	`NCT00074841` - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India	Phase 2/Phase 3
Recruiting	`NCT04416945` - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic	N/A
Completed	`NCT00314899` - Fetal Immunity to Falciparum Malaria
Completed	`NCT02867059` - SJ733 Induced Blood Stage Malaria Challenge Study	Phase 1
Completed	`NCT00701961` - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy	Phase 2/Phase 3
Completed	`NCT00338520` - Hyperphenylalaninemia in Cerebral Malaria	N/A
Completed	`NCT00707200` - The Cytoadherence in Pediatric Malaria (CPM) Study	N/A
Completed	`NCT00393757` - Malaria Transmission and Immunity in Highland Kenya
Completed	`NCT03783299` - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic	Phase 4
Completed	`NCT02614404` - Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria	Phase 1
Completed	`NCT00358332` - Phase I Pediatric FMP2.1/AS02A Trial in Mali	Phase 1
Completed	`NCT00730782` - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers	Phase 1
Completed	`NCT00349713` - FMP2.1 Trial in Bandiagara, Mali	Phase 1
Recruiting	`NCT05052502` - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand	N/A
Completed	`NCT04093765` - Mass Screening and Treatment for Reduction of Falciparum Malaria	N/A
Completed	`NCT03764527` - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar	Phase 4